Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Get full text

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations by Cheunkarndee, Tia, Guo, Matthew Z., Houseknecht, Stefanie, Feliciano, Josephine L., Hann, Christine L., Lam, Vincent K., Levy, Benjamin P., Murray, Joseph C., Brahmer, Julie R., Forde, Patrick M., Marrone, Kristen A., Scott, Susan C.

Get full text

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies by Brahmer, Julie R., Johnson, Melissa L., Cobo, Manuel, Viteri, Santiago, Sarto, Juan Coves, Sukari, Ammar, Awad, Mark M., Salgia, Ravi, Papadimitrakopoulou, Vali A., Rajan, Arun, Bandyopadhyay, Nibedita, Allred, Alicia J., Wade, Mark, Mason, Gary E., Zudaire, Enrique, Knoblauch, Roland E., Stone, Nicole, Lorenzi, Matthew V., Hassan, Raffit

Get full text

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC by Reuss, Joshua E., Brigham, Emily, Psoter, Kevin J., Voong, Khinh Ranh, Shankar, Bairavi, Ettinger, David S., Marrone, Kristen A., Hann, Christine L., Levy, Benjamin, Feliciano, Josephine L., Brahmer, Julie R., Feller-Kopman, David, Lerner, Andrew D., Lee, Hans, Yarmus, Lonny, Hales, Russell K., D’Alessio, Franco, Danoff, Sonye K., Forde, Patrick M., Suresh, Karthik, Naidoo, Jarushka

Get full text

Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer by Fathi, Amir T., MD, Brahmer, Julie R., MD, MSc

Get full text